PURPOSE: To study the influence of different medications on retinal vessel diameters. DESIGN: Cross-sectional study. METHODS: Retinal photographs in the Beaver Dam Eye Study (n = 4926, aged 43 to 84 years) were digitized, and the diameters of retinal vessels were measured. Participants' current medications were recorded at the examination. RESULTS: There were few significant associations between medication use and retinal vessel diameters. After adjusting for age, blood pressure, and other factors, participants who were using topical beta-blocker eyedrops had narrower retinal arteriolar (P = .05) and venular (P = .006) diameters than nonusers. Systemic beta-blocker was not associated with retinal vessel diameter size. CONCLUSION: We found few associations between current medication use and retinal vessel diameter. Retinal vessels were narrowed in those taking antiglaucoma medications, most strikingly in those prescribed topical beta-blockers, although such a relationship could not be established among those using systemic beta-blockers.
PURPOSE: To study the influence of different medications on retinal vessel diameters. DESIGN: Cross-sectional study. METHODS: Retinal photographs in the Beaver Dam Eye Study (n = 4926, aged 43 to 84 years) were digitized, and the diameters of retinal vessels were measured. Participants' current medications were recorded at the examination. RESULTS: There were few significant associations between medication use and retinal vessel diameters. After adjusting for age, blood pressure, and other factors, participants who were using topical beta-blocker eyedrops had narrower retinal arteriolar (P = .05) and venular (P = .006) diameters than nonusers. Systemic beta-blocker was not associated with retinal vessel diameter size. CONCLUSION: We found few associations between current medication use and retinal vessel diameter. Retinal vessels were narrowed in those taking antiglaucoma medications, most strikingly in those prescribed topical beta-blockers, although such a relationship could not be established among those using systemic beta-blockers.
Authors: Ronald Klein; Chelsea E Myers; Barbara E K Klein; Bernard Zinman; Robert Gardiner; Samy Suissa; Alan R Sinaiko; Sandra M Donnelly; Paul Goodyer; Trudy Strand; Michael Mauer Journal: Arch Ophthalmol Date: 2010-02
Authors: Ivan Y-F Leung; Shenghan Lai; Shiquan Ren; John Kempen; Ronald Klein; Mark O M Tso; Hong C Lai Journal: Am J Ophthalmol Date: 2008-07-26 Impact factor: 5.258
Authors: Chelsea E Myers; Ronald Klein; Michael D Knudtson; Kristine E Lee; Ronald Gangnon; Tien Y Wong; Barbara E K Klein Journal: Ophthalmology Date: 2012-08-20 Impact factor: 12.079
Authors: Fergus N Doubal; Rosemarie de Haan; Thomas J MacGillivray; Petra E Cohn-Hokke; Bal Dhillon; Martin S Dennis; Joanna M Wardlaw Journal: Int J Stroke Date: 2010-12 Impact factor: 5.266